PharmaCyte Biotech, Inc. (PMCB)
0.3422
0.00 (0.00%)
USD |
NASDAQ |
Oct 20, 16:00
0.3411
0.00 (0.00%)
After-Hours: 20:00
PharmaCyte Biotech Debt to Equity Ratio : 0.00 for July 31, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| July 31, 2026 | 0.00 |
| April 30, 2026 | 0.00 |
| January 31, 2026 | 0.00 |
| October 31, 2025 | 0.00 |
| July 31, 2025 | 0.00 |
| April 30, 2025 | 0.00 |
| January 31, 2025 | 0.00 |
| October 31, 2024 | 0.00 |
| July 31, 2024 | 0.00 |
| April 30, 2024 | 0.00 |
| January 31, 2024 | 0.00 |
| October 31, 2023 | 0.00 |
| July 31, 2023 | 0.00 |
| April 30, 2023 | 0.00 |
| January 31, 2023 | 0.00 |
| October 31, 2022 | 0.00 |
| July 31, 2022 | 0.00 |
| April 30, 2022 | 0.00 |
| January 31, 2022 | 0.00 |
| October 31, 2021 | 0.00 |
| July 31, 2021 | 0.0022 |
| April 30, 2021 | 0.0076 |
| January 31, 2021 | 0.0099 |
| October 31, 2020 | 0.0137 |
| July 31, 2020 | 0.012 |
| Date | Value |
|---|---|
| April 30, 2020 | 0.0148 |
| January 31, 2020 | 0.00 |
| October 31, 2019 | 0.0052 |
| July 31, 2019 | 0.00 |
| April 30, 2019 | 0.00 |
| January 31, 2019 | 0.00 |
| October 31, 2018 | 0.00 |
| July 31, 2018 | 0.00 |
| April 30, 2018 | 0.00 |
| January 31, 2018 | 0.00 |
| October 31, 2017 | 0.00 |
| July 31, 2017 | 0.00 |
| April 30, 2017 | 0.00 |
| January 31, 2017 | 0.00 |
| October 31, 2016 | 0.00 |
| July 31, 2016 | 0.00 |
| April 30, 2016 | 0.00 |
| January 31, 2016 | 0.00 |
| October 31, 2015 | 0.00 |
| July 31, 2015 | 0.00 |
| April 30, 2015 | 0.00 |
| January 31, 2015 | 0.00 |
| October 31, 2014 | 0.00 |
| July 31, 2014 | 0.016 |
| April 30, 2014 | 0.0161 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Agenus, Inc. | -1.458 |
| Amgen, Inc. | 4.903 |
| Anika Therapeutics, Inc. | 0.1839 |
| BioCryst Pharmaceuticals, Inc. | -1.842 |
| Imunon, Inc. | 1.873 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 36.71M |
| Total Liabilities (Quarterly) | 6.897M |
| Shareholders Equity (Quarterly) | 29.40M |
| Current Ratio | 40.29 |